Palvella Therapeutics, Inc. 8-K Filing

Ticker: PVLA · Form: 8-K · Filed: Mar 31, 2026 · CIK: 0001583648

Palvella Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyPalvella Therapeutics, Inc. (PVLA)
Form Type8-K
Filed DateMar 31, 2026
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Palvella Therapeutics, Inc. (ticker: PVLA) to the SEC on Mar 31, 2026.

What are the key financial figures in this filing?

Key dollar amounts include: $0.001 (nge on which registered Common Stock, $0.001 par value per share PVLA The Nasdaq).

How long is this filing?

Palvella Therapeutics, Inc.'s 8-K filing is 2 pages with approximately 651 words. Estimated reading time is 3 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 651 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2026-03-31 08:00:11

Key Financial Figures

  • $0.001 — nge on which registered Common Stock, $0.001 par value per share PVLA The Nasdaq

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On March 31, 2026, Palvella Therapeutics, Inc. (the " Company ") announced its financial results for the year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the " Securities Act "), or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On March 31, 2026, the Company will hold its earnings call and use a slide presentation in conjunction with the earnings call. A copy of the presentation is furnished herewith as Exhibit 99.2, and incorporated herein by reference. The information furnished pursuant to Item 7.01, including Exhibit 99.2, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Palvella Therapeutics, Inc., dated March 31, 2026* 99.2 Earnings Call Presentation of Palvella Therapeutics, Inc., dated March 31, 2026* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Furnished herewith

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Palvella Therapeutics, Inc. Date: March 31, 2026 By: /s/ Matthew Korenberg Matthew Korenberg Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.